Cargando…
LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients
So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of informati...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730493/ https://www.ncbi.nlm.nih.gov/pubmed/33291445 http://dx.doi.org/10.3390/ijms21239287 |
_version_ | 1783621696696090624 |
---|---|
author | Wanka, Giulia Schmoeckel, Elisa Mayr, Doris Fuerst, Sophie Kuhn, Christina Mahner, Sven Knabl, Julia Karsten, Maria Margarete Dannecker, Christian Heidegger, Helene H. Vattai, Aurelia Jeschke, Udo Jueckstock, Julia |
author_facet | Wanka, Giulia Schmoeckel, Elisa Mayr, Doris Fuerst, Sophie Kuhn, Christina Mahner, Sven Knabl, Julia Karsten, Maria Margarete Dannecker, Christian Heidegger, Helene H. Vattai, Aurelia Jeschke, Udo Jueckstock, Julia |
author_sort | Wanka, Giulia |
collection | PubMed |
description | So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of information about LDOC1 and its exact functionality, this study focuses on the expression of LDOC1 in vulvar carcinoma cells and its surrounding immune cells as well as its correlation to clinicopathological characteristics and prognosis. Additionally, a possible regulation of LDOC1 in vulvar cancer cell lines via the NF-κB signaling pathway was analyzed. Vulvar carcinoma sections of 157 patients were immunohistochemically stained and examined regarding LDOC1 expression by using the immunoreactive score (IRS). To characterize LDOC1-positively stained immune cell subpopulations, immunofluorescence double staining was performed. The effect of the NF-κB inhibitor C-DIM 12 (3,3′-[(4-chlorophenyl)methylene]bis[1 H-indole]) on vulvar cancer cell lines A431 and SW 954 was measured according to MTT and BrdU assays. Baseline expression levels of LDOC1 in the vulvar cancer cell lines A431 and SW 954 was analyzed by real-time PCR. LDOC1 was expressed by about 90% of the cancer cells in the cytoplasm and about half of the cells in the nucleus. Cytoplasmatic expression of LDOC1 was associated with decreased ten-year overall survival of the patient, whereas nuclear staining showed a negative association with disease-free survival. Infiltrating immune cells were mainly macrophages followed by regulatory T cells. Incubation with C-DIM 12 decreased the cell viability and proliferation of vulvar cancer cell line A431, but not of cell line SW 954. LDOC1 expression on mRNA level was twice as high in the cell line A431 compared to the cell line SW 954. Overexpression of LDOC1 was associated with unfavorable overall and disease-free survival. Tumor growth could be inhibited by C-DIM 12 in vitro if the expressed LDOC1 level was high enough. |
format | Online Article Text |
id | pubmed-7730493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77304932020-12-12 LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients Wanka, Giulia Schmoeckel, Elisa Mayr, Doris Fuerst, Sophie Kuhn, Christina Mahner, Sven Knabl, Julia Karsten, Maria Margarete Dannecker, Christian Heidegger, Helene H. Vattai, Aurelia Jeschke, Udo Jueckstock, Julia Int J Mol Sci Article So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients’ survival and prognosis. Due to the lack of information about LDOC1 and its exact functionality, this study focuses on the expression of LDOC1 in vulvar carcinoma cells and its surrounding immune cells as well as its correlation to clinicopathological characteristics and prognosis. Additionally, a possible regulation of LDOC1 in vulvar cancer cell lines via the NF-κB signaling pathway was analyzed. Vulvar carcinoma sections of 157 patients were immunohistochemically stained and examined regarding LDOC1 expression by using the immunoreactive score (IRS). To characterize LDOC1-positively stained immune cell subpopulations, immunofluorescence double staining was performed. The effect of the NF-κB inhibitor C-DIM 12 (3,3′-[(4-chlorophenyl)methylene]bis[1 H-indole]) on vulvar cancer cell lines A431 and SW 954 was measured according to MTT and BrdU assays. Baseline expression levels of LDOC1 in the vulvar cancer cell lines A431 and SW 954 was analyzed by real-time PCR. LDOC1 was expressed by about 90% of the cancer cells in the cytoplasm and about half of the cells in the nucleus. Cytoplasmatic expression of LDOC1 was associated with decreased ten-year overall survival of the patient, whereas nuclear staining showed a negative association with disease-free survival. Infiltrating immune cells were mainly macrophages followed by regulatory T cells. Incubation with C-DIM 12 decreased the cell viability and proliferation of vulvar cancer cell line A431, but not of cell line SW 954. LDOC1 expression on mRNA level was twice as high in the cell line A431 compared to the cell line SW 954. Overexpression of LDOC1 was associated with unfavorable overall and disease-free survival. Tumor growth could be inhibited by C-DIM 12 in vitro if the expressed LDOC1 level was high enough. MDPI 2020-12-05 /pmc/articles/PMC7730493/ /pubmed/33291445 http://dx.doi.org/10.3390/ijms21239287 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wanka, Giulia Schmoeckel, Elisa Mayr, Doris Fuerst, Sophie Kuhn, Christina Mahner, Sven Knabl, Julia Karsten, Maria Margarete Dannecker, Christian Heidegger, Helene H. Vattai, Aurelia Jeschke, Udo Jueckstock, Julia LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title | LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title_full | LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title_fullStr | LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title_full_unstemmed | LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title_short | LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients |
title_sort | ldoc1 as negative prognostic marker for vulvar cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730493/ https://www.ncbi.nlm.nih.gov/pubmed/33291445 http://dx.doi.org/10.3390/ijms21239287 |
work_keys_str_mv | AT wankagiulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT schmoeckelelisa ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT mayrdoris ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT fuerstsophie ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT kuhnchristina ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT mahnersven ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT knabljulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT karstenmariamargarete ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT danneckerchristian ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT heideggerheleneh ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT vattaiaurelia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT jeschkeudo ldoc1asnegativeprognosticmarkerforvulvarcancerpatients AT jueckstockjulia ldoc1asnegativeprognosticmarkerforvulvarcancerpatients |